U.S. Viral Vector and Plasmid DNA Manufacturing Market to Reach USD 11,315.21 Million by 2032, Growing at 19.9% CAGR: Polaris Market Research

According to a new report by Polaris Market Research, the U.S. viral vector and plasmid DNA manufacturing market was valued at USD 2,204.51 million in 2023 and is projected to reach USD 11,315.21 million by 2032, expanding at a CAGR of 19.9% over the forecast period (2024–2032). Growth is underpinned by rising demand for gene and cell therapies, expanding viral vector manufacturing capacity, and accelerating technological advancements across biopharmaceutical end-use industries.

What Is Driving U.S. Viral Vector and Plasmid DNA Manufacturing Market Growth?

Demand is climbing as the rising incidence of genetic disorders and cancer converges with growing government investment in advanced therapeutics. Manufacturers and end users are prioritizing gene therapy and cell therapy development, pushing viral vector and plasmid DNA adoption across the U.S. pharmaceutical and biopharmaceutical sector. Polaris analysts note that an estimated 10,000 to 25,000 individuals in the U.S. are affected by spinal muscular atrophy alone, positioning gene-therapy-driven demand for sustained double-digit growth through 2032, with the cancer segment emerging as the largest revenue contributor and genetic disorders posting strong incremental gains.

Key Trends Shaping the U.S. Viral Vector and Plasmid DNA Manufacturing Industry

Rising Demand for Gene and Cell Therapies

The growing incidence of genetic disorders and cancer is driving demand for gene and cell therapies that rely on viral vectors for efficient delivery of genetic material. CAR-T cell therapy has shown strong results in acute lymphoblastic leukemia and non-Hodgkin lymphoma, and strategic collaborations such as Charles River Laboratories' June 2024 partnership with Captain T Cell to manufacture plasmid DNA and retrovirus vectors for a Phase I solid-tumor trial continue to expand market capacity.

Growing Technological Advancements

Automated manufacturing platforms are integrating cell culture and purification into unified systems, reducing manual intervention and improving reproducibility. In May 2024, Charles River Laboratories launched Modular and Fast Track viral vector technology transfer frameworks, enabling accelerated method transfer to its Maryland-based center of excellence within nine months, strengthening the company's position in the industry landscape.

Capacity Expansion and Investment Activity

Leading manufacturers continue to expand U.S. production footprints to meet rising demand. Thermo Fisher Scientific broadened its Lexington, Massachusetts facility in March 2025 with 100,000 square feet of additional GMP production capacity, following earlier expansions in Plainville, Massachusetts and a cGMP plasmid DNA facility in Carlsbad, California signaling continued capital investment across the market outlook.

👉 Explore The Complete Comprehensive Report Here: https://www.polarismarketresearch.com/industry-analysis/us-viral-vector-and-plasmid-dna-manufacturing-market

Market Segmentation: Breaking Down the U.S. Viral Vector and Plasmid DNA Manufacturing Market

Polaris segments the U.S. viral vector and plasmid DNA manufacturing market by disease, end-use, vector type, and workflow, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Disease

The cancer segment led the market in 2023, supported by a wave of FDA-approved gene therapies for oncology and the rising incidence of cancer nationwide the CDC reported 1,777,566 new cancer cases in 2021 alone. The progression toward personalized medicine, in which gene and cell therapies are tailored to a patient's genetic profile, continues to reinforce demand in this segment. Genetic disorders form another significant category, reflecting search intent around "gene therapy for genetic disorders."

By End-Use

Pharmaceutical and biopharmaceutical companies represent the fastest-growing end-use segment, driven by heavy R&D investment in gene and cell therapies and a supportive regulatory environment that shortens time-to-market. Research institutes make up the second end-use category, reflecting continued academic and translational research activity in vector development.

By Vector Type

Polaris tracks the market across Adeno-Associated Virus (AAV), Adenovirus, Lentivirus, Plasmids, Retrovirus, and other vector formats, each addressing distinct therapeutic and manufacturing requirements as gene- and cell-therapy pipelines expand across oncology, infectious disease, and rare genetic disorders.

By Workflow

On a workflow basis, the market spans upstream manufacturing covering vector amplification and expansion and vector recovery/harvesting and downstream manufacturing, covering fill-finish and purification. Investment in automated, integrated platforms is increasingly bridging these two workflow stages to improve throughput and vector quality.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the U.S. viral vector and plasmid DNA manufacturing market, this report benchmarks market share, segment-level trends, and forecast data by disease, end-use, vector type, and workflow to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing CDMO suppliers, investors sizing entry points, and strategy teams tracking cell and gene therapy manufacturing as a growth adjacency.

👉 Explore the Full U.S. Viral Vector and Plasmid DNA Manufacturing Market Report: https://www.polarismarketresearch.com/industry-analysis/us-viral-vector-and-plasmid-dna-manufacturing-market

Competitive Landscape: Leading U.S. Viral Vector and Plasmid DNA Manufacturing Companies

Key players profiled in the report include Bio-Rad Laboratories, Inc., Catalent Inc., Charles River Laboratories (Cobra Biologics), Genezen, Promega Corporation, RegenxBio, Inc., Revvity (SIRION Biotech), Thermo Fisher Scientific, Inc., Virovek Incorporation, and Waisman Biomanufacturing, who are focusing on capacity expansion, product launches, and strategic partnerships to strengthen their position across the cancer and pharmaceutical/biopharmaceutical segments outlined above. Recent moves include Charles River's January 2024 launch of its off-the-shelf Rep/Cap plasmid offering for AAV-based gene therapy programs and Vigene Biosciences' February 2025 collaboration with an oncology biotech for long-term lentiviral vector supply, both aimed at deepening share in the U.S. market.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Smart Indoor Gardening System Market

L-citrulline Market

Drill Pipe Market

Cell & Gene Therapy Bioanalytical Testing Services Market

L-citrulline Market

Platelet Rich Plasma (PRP) Market

Home Water Filtration Market

E-Fuel Market